187.28

0.13% 0.255

Astrazeneca Plc (AZN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt AZN? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$187.03

Offen:

$188.26

24-Stunden-Volumen:

982.09K

Relative Volume:

0.52

Marktkapitalisierung:

$290.44B

Einnahmen:

$60.48B

Nettoeinkommen (Verlust:

$10.40B

KGV:

56.25

EPS:

3.3297

Netto-Cashflow:

$8.05B

1W Leistung:

+1.43%

1M Leistung:

-1.30%

6M Leistung:

+100.69%

1J Leistung:

+165.98%

1-Tages-Spanne:

$186.91

$188.61

1-Wochen-Bereich:

$184.98

$191.50

52-Wochen-Spanne:

$68.61

$212.71

Astrazeneca Plc Stock (AZN) Company Profile

Firmenname

Astrazeneca Plc

Sektor

Healthcare (1110)

Branche

Drug Manufacturers - General (20)

Telefon

Adresse

Mitarbeiter

96,100

Twitter

@AstraZeneca

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

AZN's Discussions on Twitter

Compare AZN vs LLY, JNJ, ABBV, MRK

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AZN Astrazeneca Plc	187.28	290.06B	60.48B	10.40B	8.05B	3.3297
LLY Lilly Eli Co	1,072.71	949.70B	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	230.69	564.11B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	212.61	381.10B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	120.28	302.33B	65.51B	8.93B	14.12B	3.5532

Astrazeneca Plc Stock (AZN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-27	Eingeleitet	Citigroup	Buy
2025-10-27	Fortgesetzt	Jefferies	Buy
2025-10-16	Herabstufung	Deutsche Bank	Hold → Sell
2025-04-15	Eingeleitet	Exane BNP Paribas	Outperform
2025-02-13	Hochstufung	UBS	Neutral → Buy
2025-02-12	Eingeleitet	Morgan Stanley	Overweight
2024-11-20	Hochstufung	UBS	Sell → Neutral
2024-11-06	Hochstufung	Deutsche Bank	Sell → Hold
2024-09-13	Herabstufung	Deutsche Bank	Hold → Sell
2024-05-30	Eingeleitet	Goldman	Buy
2024-04-16	Hochstufung	Deutsche Bank	Sell → Hold
2024-02-08	Herabstufung	Deutsche Bank	Hold → Sell
2024-01-23	Eingeleitet	Morgan Stanley	Overweight
2024-01-16	Fortgesetzt	UBS	Sell
2024-01-03	Herabstufung	Jefferies	Buy → Hold
2023-12-18	Eingeleitet	HSBC Securities	Buy
2023-09-25	Hochstufung	Jefferies	Hold → Buy
2023-07-14	Eingeleitet	HSBC Securities	Buy
2023-07-12	Hochstufung	UBS	Neutral → Buy
2023-07-05	Herabstufung	Deutsche Bank	Buy → Hold
2023-04-11	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-01-05	Eingeleitet	BMO Capital Markets	Outperform
2022-09-15	Herabstufung	Credit Suisse	Outperform → Neutral
2022-09-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-08-29	Hochstufung	Argus	Hold → Buy
2022-06-14	Herabstufung	UBS	Buy → Neutral
2022-02-11	Hochstufung	DZ Bank	Sell → Hold
2021-12-07	Herabstufung	Jefferies	Buy → Hold
2021-08-12	Fortgesetzt	JP Morgan	Overweight
2021-04-12	Herabstufung	Argus	Buy → Hold
2021-03-16	Hochstufung	Jefferies	Hold → Buy
2021-02-25	Hochstufung	UBS	Neutral → Buy
2021-01-15	Eingeleitet	Deutsche Bank	Buy
2020-12-07	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-11-30	Hochstufung	UBS	Sell → Neutral
2020-11-11	Hochstufung	HSBC Securities	Reduce → Hold
2020-09-29	Eingeleitet	Berenberg	Buy
2019-11-22	Eingeleitet	SVB Leerink	Outperform
2019-10-25	Hochstufung	Liberum	Hold → Buy
2019-04-02	Herabstufung	UBS	Neutral → Sell
2019-02-05	Eingeleitet	Exane BNP Paribas	Outperform
2019-01-25	Hochstufung	Shore Capital	Hold → Buy
2018-12-11	Fortgesetzt	Jefferies	Hold
2018-10-09	Eingeleitet	Guggenheim	Buy
2018-08-16	Herabstufung	Jefferies	Buy → Hold
2018-03-19	Hochstufung	Jefferies	Hold → Buy
2018-02-06	Bestätigt	Leerink Partners	Mkt Perform
2018-02-05	Bestätigt	Bernstein	Outperform
2018-01-18	Bestätigt	Leerink Partners	Mkt Perform
2017-12-29	Hochstufung	JP Morgan	Neutral → Overweight
2017-10-16	Hochstufung	Credit Suisse	Neutral → Outperform
2017-09-25	Hochstufung	Exane BNP Paribas	Neutral → Outperform
2017-09-22	Hochstufung	Bernstein	Mkt Perform → Outperform

Alle ansehen

Astrazeneca Plc Aktie (AZN) Neueste Nachrichten

12:33 PM

AstraZeneca Unit Keeps Cancer Therapy IP Despite Stada Jab - Law360

12:33 PM

10:33 AM

Astrazeneca Pharma India March-quarter PAT 448.8 million rupees - marketscreener.com

10:33 AM

07:18 AM

AstraZeneca breast cancer drug camizestrant recommended for EU approval - Investing.com

07:18 AM

07:17 AM

Datroway extends survival in TNBC as AstraZeneca (NYSE: AZN) gains US ok - Stock Titan

07:17 AM

07:11 AM

AstraZeneca's Buy Rating Reiterated as BofA Notes 'Busy' Pipeline Path; Estimates Revised - marketscreener.com

07:11 AM

07:09 AM

CHMP backs AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2‑positive solid tumours in EU - Stock Titan

07:09 AM

07:05 AM

AstraZeneca plc stock (GB0009895292): oncology approvals and home-market context for UK investors - AD HOC NEWS

07:05 AM

06:28 AM

Oncology Medicine Development Keeps AstraZeneca Within FTSE 350 - Kalkine Media

06:28 AM

05:53 AM

AstraZeneca (LSE:AZN) Draws Market Focus as Share Momentum Moderates - Kalkine Media

05:53 AM

03:23 AM

AstraZeneca PLC stock (US6549022043): cancer portfolio and pipeline in focus after latest oncology d - AD HOC NEWS

03:23 AM

02:36 AM

AstraZeneca PLC stock (US6549022043): cancer pipeline and diabetes deal keep investors watching - AD HOC NEWS

02:36 AM

02:33 AM

EU panel backs AstraZeneca breast cancer drug camizestrant By Investing.com - Investing.com Nigeria

02:33 AM

AstraZeneca's Enhertu Recommended For EU Approval In HER2-positive Solid Tumours - DirectorsTalk Interviews

02:33 AM

02:20 AM

AstraZeneca says Datroway approved in US for 1L triple-negative BC - marketscreener.com

02:20 AM

May 25, 2026

Sir Pascal Soriot: Veterinary Scientist, Pharmaceutical Transformer, and Executive Director and CEO of AstraZeneca - BBN Times

May 25, 2026

AstraZeneca plc stock (GB0009895292): FDA approval for Datroway puts oncology pipeline in the spotli - AD HOC NEWS

May 25, 2026

AstraZeneca Maintains FTSE Presence Through Oncology and Global Healthcare - Kalkine Media

May 25, 2026

AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC - Pharmaceutical Technology

May 25, 2026